Biological agents offer good control of rheumatoid arthritis, but the long-term benefits of achieving low disease activity with a biological agent plus Methotrexate or Methotrexate alone are unclear.
The OPTIMA trial has assessed different treatment adjustment strategies in patients with early rheumatoid arthritis attaining ( or not ) stable low disease activity with Adalimumab [ Humira ] plus Methotrexate or Methotrexate monotherapy.
This trial was done at 161 sites worldwide. Patients with early ( less than 1 year duration ) rheumatoid arthritis naive to Methotrexate were randomly allocated ( by interactive voice response system, in a 1:1 ratio, block size four ) to Adalimumab ( 40 mg every other week ) plus Methotrexate ( initiated at 7.5 mg/week, increased by 2.5 mg every 1-2 weeks to a maximum weekly dose of 20 mg by week 8 ) or placebo plus Methotrexate for 26 weeks ( period 1 ).
Patients in the Adalimumab plus Methotrexate group who completed period 1 and achieved the stable low disease activity target ( 28-joint disease activity score with C-reactive protein [ DAS28 ] less than 3.2 at weeks 22 and 26 ) were randomised to Adalimumab-continuation or Adalimumab-withdrawal for an additional 52 weeks ( period 2 ).
Patients achieving the target with initial Methotrexate continued Methotrexate-monotherapy. Inadequate responders were offered Adalimumab plus Methotrexate.
All patients and investigators were masked to treatment allocation in period 1.
During period 2, treatment reallocation of patients who achieved the target was masked to patients and investigators; patients who did not achieve the target remained masked to original randomisation, but were aware of the subsequent assignment.
The primary endpoint was a composite measure of DAS28 of less than 3.2 at week 78 and radiographic non-progression from baseline to week 78, compared between Adalimumab-continuation and Methotrexate-monotherapy.
Adverse events were monitored throughout period 2.
The study was done during the period 2006-2010. 1636 patients were assessed and 1032 were randomised in period 1 ( 515 to Adalimumab plus Methotrexate; 517 to placebo plus Methotrexate ).
466 patients in the Adalimumab plus Methotrexate group completed period 1; 207 achieved the stable low disease activity target, of whom 105 were rerandomised to Adalimumab-continuation.
460 patients in the placebo plus Methotrexate group completed period 1; 112 achieved the stable low disease activity target and continued Methotrexate-monotherapy. 73 of 105 ( 70% ) patients in the Adalimumab-continuation group and 61 of 112 ( 54% ) patients in the Methotrexate-monotherapy group achieved the primary endpoint at week 78 ( mean difference 15%; p=0.0225 ).
Patients achieving the stable low disease activity target on Adalimumab plus Methotrexate who withdrew Adalimumab mostly maintained their good responses.
Overall, 706 of 926 patients in period 2 had an adverse event, of which 82 were deemed serious; however, distribution of adverse events did not differ between groups.
In conclusion, the treatment to a stable low disease activity target resulted in improved clinical, functional, and structural outcomes, with both Adalimumab-continuation and Methotrexate-monotherapy.
However, a higher proportion of patients treated with initial Adalimumab plus Methotrexate achieved the low disease activity target compared with those initially treated with Methotrexate alone.
Outcomes were much the same whether Adalimumab was continued or withdrawn in patients who initially responded to Adalimumab plus Methotrexate. ( Xagena )
Smolen JS et al, Lancet 2014; 383: 321-332